Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FHTX NASDAQ:GANX NASDAQ:LFCR NASDAQ:TVRD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$5.15-5.2%$5.40$2.94▼$10.25$306.96M3.0579,196 shs98,046 shsGANXGain Therapeutics$1.73+1.2%$1.69$1.33▼$3.19$61.47M0.14559,296 shs299,290 shsLFCRLifecore Biomedical$7.01-3.4%$7.57$4.33▼$8.85$271.58M0.64112,431 shs112,195 shsTVRDTvardi Therapeutics$32.84+3.2%$26.34$8.13▼$34.31$298.39M0.2519,027 shs20,833 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-5.16%-2.28%+9.34%+13.44%-46.69%GANXGain Therapeutics+1.17%-9.90%+18.49%-3.89%+36.22%LFCRLifecore Biomedical-3.44%-9.08%-2.91%+2.64%+44.83%TVRDTvardi Therapeutics+3.21%+14.19%+36.10%+25.78%+3,283,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFHTXFoghorn Therapeutics$5.15-5.2%$5.40$2.94▼$10.25$306.96M3.0579,196 shs98,046 shsGANXGain Therapeutics$1.73+1.2%$1.69$1.33▼$3.19$61.47M0.14559,296 shs299,290 shsLFCRLifecore Biomedical$7.01-3.4%$7.57$4.33▼$8.85$271.58M0.64112,431 shs112,195 shsTVRDTvardi Therapeutics$32.84+3.2%$26.34$8.13▼$34.31$298.39M0.2519,027 shs20,833 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFHTXFoghorn Therapeutics-5.16%-2.28%+9.34%+13.44%-46.69%GANXGain Therapeutics+1.17%-9.90%+18.49%-3.89%+36.22%LFCRLifecore Biomedical-3.44%-9.08%-2.91%+2.64%+44.83%TVRDTvardi Therapeutics+3.21%+14.19%+36.10%+25.78%+3,283,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFHTXFoghorn Therapeutics 3.17Buy$10.67107.12% UpsideGANXGain Therapeutics 3.00Buy$8.00362.43% UpsideLFCRLifecore Biomedical 2.50Moderate Buy$8.0014.12% UpsideTVRDTvardi Therapeutics 3.00Buy$64.2595.65% UpsideCurrent Analyst Ratings BreakdownLatest GANX, FHTX, LFCR, and TVRD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025GANXGain TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.009/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight8/13/2025GANXGain TherapeuticsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $6.007/14/2025TVRDTvardi TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$62.007/11/2025TVRDTvardi TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$52.007/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.006/12/2025TVRDTvardi TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$78.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFHTXFoghorn Therapeutics$22.60M12.88N/AN/A($0.82) per share-6.28GANXGain Therapeutics$50K1,243.87N/AN/A$0.28 per share6.18LFCRLifecore Biomedical$128.87M2.03N/AN/A$0.04 per share175.25TVRDTvardi Therapeutics$7.14M43.14N/AN/A($3.02) per share-10.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFHTXFoghorn Therapeutics-$86.62M-$1.19N/AN/AN/A-311.90%N/A-28.00%11/3/2025 (Estimated)GANXGain Therapeutics-$20.41M-$0.63N/AN/AN/AN/A-289.10%-155.11%11/13/2025 (Estimated)LFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)TVRDTvardi Therapeutics-$70.87MN/A0.00∞N/A-678.79%-565.83%-66.71%N/ALatest GANX, FHTX, LFCR, and TVRD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/3/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/14/2025Q2 2025TVRDTvardi Therapeutics-$0.51-$1.00-$0.49-$1.00N/AN/A8/12/2025Q2 2025GANXGain Therapeutics-$0.17-$0.19-$0.02-$0.19N/AN/A8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 million8/5/2025Q2 2025FHTXFoghorn Therapeutics-$0.31-$0.28+$0.03-$0.28$7.62 million$7.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/ATVRDTvardi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFHTXFoghorn TherapeuticsN/A2.622.62GANXGain Therapeutics0.091.791.79LFCRLifecore Biomedical113.762.841.77TVRDTvardi TherapeuticsN/A4.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFHTXFoghorn Therapeutics61.55%GANXGain Therapeutics11.97%LFCRLifecore Biomedical83.36%TVRDTvardi Therapeutics44.66%Insider OwnershipCompanyInsider OwnershipFHTXFoghorn Therapeutics7.58%GANXGain Therapeutics7.18%LFCRLifecore Biomedical32.20%TVRDTvardi Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFHTXFoghorn Therapeutics12056.53 million52.25 millionOptionableGANXGain Therapeutics2035.95 million33.37 millionOptionableLFCRLifecore Biomedical69037.41 million25.36 millionOptionableTVRDTvardi Therapeutics809.38 million9.09 millionN/AGANX, FHTX, LFCR, and TVRD HeadlinesRecent News About These CompaniesTvardi Therapeutics (NASDAQ:TVRD) Is In A Good Position To Deliver On Growth PlansAugust 31, 2025 | finance.yahoo.comTvardi Therapeutics (NASDAQ:TVRD) Trading Down 0.9% - Here's WhyAugust 24, 2025 | marketbeat.comTvardi Therapeutics to Participate in the Cantor Global Healthcare ConferenceAugust 21, 2025 | theglobeandmail.comTvardi Therapeutics (NASDAQ:TVRD) Releases Quarterly Earnings Results, Misses Estimates By $0.49 EPSAugust 16, 2025 | marketbeat.comTvardi Therapeutics expects cash to fund operations into Q4 2026August 15, 2025 | msn.comTvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last yearAugust 15, 2025 | msn.comTvardi: Q2 Earnings SnapshotAugust 14, 2025 | timesunion.comTTvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business UpdateAugust 14, 2025 | finance.yahoo.comRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15, 2025 | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | businesswire.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comTvardi Therapeutics Inc News (TVRD) - Investing.comJune 27, 2025 | investing.comTVRD Tvardi Therapeutics, Inc.June 19, 2025 | seekingalpha.comPiper Sandler initiates Tvardi Therapeutics stock with overweight ratingJune 13, 2025 | uk.investing.comRecently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock UpsideJune 12, 2025 | benzinga.comTvardi Therapeutics Inc (TVRD)June 7, 2025 | investing.comTvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary FibrosisMay 27, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGANX, FHTX, LFCR, and TVRD Company DescriptionsFoghorn Therapeutics NASDAQ:FHTX$5.15 -0.28 (-5.16%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$5.20 +0.05 (+0.97%) As of 09/10/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Gain Therapeutics NASDAQ:GANX$1.73 +0.02 (+1.17%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$1.72 -0.01 (-0.52%) As of 09/10/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Lifecore Biomedical NASDAQ:LFCR$7.01 -0.25 (-3.44%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$7.00 0.00 (-0.07%) As of 09/10/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Tvardi Therapeutics NASDAQ:TVRD$32.84 +1.02 (+3.21%) As of 09/10/2025 04:00 PM EasternCara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
